•     Testimonials      •     Verdicts      •     Bios      •

Contact Us

Case Review Form
* Denotes required field.

Injury Topic
(Name of Drug or Device)

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Please describe your case:

Date of Incident
(mm-dd-yyyy):

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Depakote


AddThis Social Bookmark Button

Depakote Has Been Linked to Birth Defects

Depakote (generic: divalproex) is used to treat certain types of seizures and convulsions. It can be prescribed alone or with other epilepsy medications. Depakote is manufactured by Abbott Laboratories and gained FDA approval in 2000. On May 3, 2007, doctors reported that expectant mothers with epilepsy who took Depakote to control seizures were at increased risk of having a child with mental deficits.

Toddlers who had been exposed in the womb to Depakote, scored seven to eight points lower on I.Q. tests at age 2 than those whose mothers had been taking other epilepsy drugs while pregnant, the study discovered. They were twice as likely to score in the range associated with mental retardation, according to the authors, who presented the findings at the annual meeting of the American Academy of Neurology in Boston. The report is consistent with several new studies finding that Depakote is more likely than other so-called anticonvulsant drugs to increase the risk of mental deficits and other birth defects, like neural tube problems.

“Depakote looks worse than the other drugs in all of these recent studies,” said Dr. Kimford J. Meador, a professor of neurology at the University of Florida and the lead author of the new study. “In all, it is compelling evidence that this drug should not be used as a first-line choice for treatment in pregnant women.” The drug’s label currently states that Depakote “has been associated with birth defects in children of women who have taken it while pregnant.”

If you or a loved one took Depakote while pregnant and gave birth to a child with mental deficits, you may be entitled to compensation. Please fill out the form at the right for a free case evaluation by a qualified defective drugs attorney. Alternatively, call 1-800-LAW-INFO (1-800-529-4636).
DepakoteRSS Feed

Epilepsy Drugs to Carry Suicide Warnings

Dec 17, 2008 | Parker Waichman Alonso LLP
Epilepsy drugs must now carry warnings about their suicide risks, the Food & Drug Administration (FDA) has announced.  The drugs subject to the new warning include those used to treat psychiatric disorders, migraine headaches and other conditions, as well as epilepsy.  Epilepsy drugs on the list are:Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR) Clonazepam (marketed as Klonopin) Clorazepate (marketed as Tranxene) Divalproex sodium (marketed as Depakote,...

Epilepsy Drugs Targeted for Black Box Suicide Warning

Jul 8, 2008 | Parker Waichman Alonso LLP
Federal regulators want the makers of epilepsy drugs to add a black box warning to their labels about their association with suicidal thoughts and behavior. The Food & Drug Administration (FDA) is set to ask an outside advisory panel for its recommendations on the proposed black box at a meeting this Thursday.   In total, 11 epilepsy drugs could get the new black box warning - the FDA's strongest safety notice. They include:Carbamazepine (marketed as Carbatrol, Equetro, Tegretol,...

New Suicide Warning for Epilepsy Drugs

Jun 12, 2008 | Parker Waichman Alonso LLP
United States drug reviewers just announced that epilepsy drugs are associated with a higher risk of suicidal thoughts and behavior.  The analysis was released this week and confirmed earlier findings.  "The effect appears consistent among the group of 11 drugs" that were reviewed, according to a summary from statistical reviewers at the Food and Drug Administration (FDA).  In the review dated May 23, the FDA staff said that there were about two more cases of suicidal...

Epilepsy Drugs to Get Suicide Warnings, FDA Confirms

Jun 6, 2008 | Parker Waichman Alonso LLP
US regulators are very close to finalizing new suicide warnings for 11 epilepsy drugs, The Wall Street Journal reported today.  This past January, the Food & Drug Administration (FDA) issued an Early Communication announcing a safety review of the epilepsy drugs after a study showed they increased patients' risk of suicidal thoughts and behavior. The 11 epilepsy drugs slated for a new suicide warning are: Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR)...

Epilepsy Drugs Double Suicide Risks, FDA Warns

Feb 2, 2008 | Parker Waichman Alonso LLP
Epilepsy drugs have been linked to a increased risk of suicidal thoughts and behavior, the Food & Drug Administration (FDA) warned this week.  According  to an FDA analysis, people taking antiepileptic drugs are twice as likely to experience suicidal thoughts or behavior than those taking placebo.The FDA began investigating if epilepsy drugs pose any suicide risk in 2005.  In doing so, the FDA analyzed almost 200 studies of 11 anti-seizure drugs, some that have been on the...

More Depakote News